Emmanuelle Clerisme-Beaty

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

Kevin R. Flaherty, Athol U. Wells, Vincent Cottin et al. · New England Journal of Medicine · 2019 · 2.3K citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacotherapy +11

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Oliver Distler, Kristin B. Highland, Martina Gahlemann et al. · New England Journal of Medicine · 2019 · 1.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

The natural history of progressive fibrosing interstitial lung diseases

Kevin K. Brown, Fernando J. Martínez, Simon Walsh et al. · European Respiratory Journal · 2020 · 288 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

Kristin B. Highland, Oliver Distler, Masataka Kuwana et al. · The Lancet Respiratory Medicine · 2021 · 212 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease

Kevin M. Brown, Athol U. Wells, Emmanuelle Clerisme-Beaty et al. · BMJ Open Respiratory Research · 2017 · 187 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +15